A composition for improving rhinitis symptoms and nasal cleaning, and its preparation method and application

Abstract

The present invention discloses a composition for improving rhinitis symptoms and nasal cleaning, as well as its preparation method and application. The composition comprises, by weight, 0.1 to 7 parts of yeast β-glucan and 0.1 to 6 parts of mussel mucin. The present invention prepares a composition for improving rhinitis symptoms and nasal cleaning by rationally combining ultra-low molecular weight yeast β-glucan, low molecular weight yeast β-glucan, medium molecular weight yeast β-glucan, high molecular weight yeast β-glucan, and mussel mucin. The composition can be effectively used for nasal cleaning of patients with nasal diseases such as acute rhinitis, chronic rhinitis, allergic rhinitis, nasal polyps, sinusitis, etc., and can also be used for nasal cleaning after nasal tumor surgery or chemotherapy.

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and particularly relates to a composition for improving rhinitis symptoms and nasal cleaning, and a preparation method and application thereof. Background Art

[0002] Rhinitis is an acute or chronic inflammation of the nasal mucosa or submucosal tissue caused by viral infection, bacterial infection, or irritants. Rhinitis leads to excessive mucus production, typically causing symptoms such as a runny nose and nasal congestion.

[0003] The nasal cavity is covered throughout by a mucosa composed of stratified or pseudostratified columnar ciliated epithelium, whose cilia move primarily from front to back toward the nasopharynx. The mucosa contains abundant serous and mucous glands and goblet cells, which produce copious secretions, coating the mucosal surface with a blanket of mucus that continuously moves backward with the movement of the cilia. The mucosa also contains a rich venous plexus, forming a spongy tissue with flexible contraction and relaxation, capable of rapidly changing its congestion state. This is a major component in regulating air temperature and humidity. Due to the unique characteristics of the nasal mucosa, it is susceptible to infection by viruses, bacteria, and fungi.

[0004] Generally, nasal cleaning solution is made of sodium chloride in aqueous solution and sprayed to the affected area through an electric nasal washer. Although it has a certain anti-inflammatory effect, it is not effective in treating allergic rhinitis and chronic rhinitis. Summary of the Invention

[0005] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention provides a composition for improving rhinitis symptoms and nasal cleaning, which can be effectively used to improve rhinitis symptoms.

[0006] The present invention also provides a method for preparing the composition.

[0007] The present invention also provides the application of the composition.

[0008] In a first aspect of the present invention, a composition for improving rhinitis symptoms and nasal cleaning is provided, comprising, by weight, 0.1 to 7 parts of yeast β-glucan and 0.1 to 6 parts of mussel mucin;

[0009] The yeast β-glucan includes ultra-low molecular weight yeast β-glucan, low molecular weight yeast β-glucan, medium molecular weight yeast β-glucan and high molecular weight yeast β-glucan.

[0010] The present invention rationally combines four yeast β-glucans of different molecular weights (ultra-low molecular weight yeast β-glucan, low molecular weight yeast β-glucan, medium molecular weight yeast β-glucan and high molecular weight yeast β-glucan) to prepare a composition for improving rhinitis symptoms and nasal cleaning, with outstanding comprehensive effects. Among them, ultra-low molecular weight yeast β-glucan can penetrate the surface layer of the skin into the dermis of the skin and can be retained in high content, with better absorption and penetration effects, can act on cells faster, regulate immune response, and achieve anti-inflammatory effects; low molecular weight yeast β-glucan can effectively penetrate into the nasal mucosa The invention can effectively prevent the nasal mucosa from being damaged and retain the nasal mucosa, and can effectively prevent the nasal mucosa from being damaged and retaining moisture. The invention can effectively prevent the nasal mucosa from being damaged and retaining moisture. The invention can effectively prevent the nasal mucosa from being damaged and retaining moisture. The invention can effectively prevent the nasal mucosa from being damaged and retaining moisture. The invention can effectively prevent the nasal mucosa from being damaged and retaining moisture.

[0011] According to some embodiments of the present invention, the molecular weight of the ultra-low molecular weight yeast β-glucan is less than 1 WDa.

[0012] According to some embodiments of the present invention, the low molecular weight yeast β-glucan has a molecular weight of 1 WDa to 50 WDa.

[0013] According to some embodiments of the present invention, the molecular weight of the medium molecular weight yeast β-glucan is 50 WDa to 200 WDa.

[0014] According to some embodiments of the present invention, the high molecular weight yeast β-glucan has a molecular weight of >200 WDa.

[0015] According to some embodiments of the present invention, the mass ratio of ultra-low molecular weight yeast β-glucan, low molecular weight yeast β-glucan, medium molecular weight yeast β-glucan and high molecular weight yeast β-glucan is 1:(1-4):(1-2):(1-3).

[0016] According to some embodiments of the present invention, the mass ratio of the ultra-low molecular weight yeast beta glucan, the low molecular weight yeast beta glucan, the medium molecular weight yeast beta glucan and the high molecular weight yeast beta glucan is 1:2:1:2.

[0017] According to some embodiments of the present invention, the yeast β-glucan has a β-1,3-linked main chain, and contains 1-2 β-1,6-linked glucose side chains on every 3-7 main chain glucose residues on average.

[0018] According to some embodiments of the present invention, the total mass of the yeast β-glucan and the mussel mucin accounts for 1% to 7% by mass of the composition.

[0019] According to some embodiments of the invention, the composition further comprises physiological seawater.

[0020] According to some embodiments of the invention, the composition further comprises sodium dihydrogen phosphate.

[0021] According to some embodiments of the present invention, the composition further comprises 0.1 to 20 parts of auxiliary materials.

[0022] According to some embodiments of the present invention, the auxiliary material includes at least one of a preservative, a thickener, a wetting agent, and a moisturizer.

[0023] According to some embodiments of the present invention, the composition further comprises 0.1 to 0.1 parts of a preservative.

[0024] According to some embodiments of the present invention, the preservative includes at least one of methylparaben, benzoic acid, sodium benzoate, phenoxyethanol, sorbic acid or sodium sorbate; preferably methylparaben.

[0025] According to some embodiments of the present invention, the composition comprises the following components in parts by weight:

[0026] Yeast β-glucan 0.1-7 parts;

[0027] 0.1-6 parts of mussel mucin;

[0028] 0.1-1 parts of preservatives;

[0029] 0.05-0.5 parts of sodium dihydrogen phosphate;

[0030] Appropriate amount of physiological seawater.

[0031] According to some preferred embodiments of the present invention, the composition comprises the following components in parts by weight:

[0032] 1-5 parts of yeast β-glucan;

[0033] 1-5 parts of mussel mucin;

[0034] 0.1-1 parts of preservatives;

[0035] 0.05-0.5 parts of sodium dihydrogen phosphate;

[0036] Appropriate amount of physiological seawater.

[0037] The second aspect of the present invention provides a method for preparing the above composition, comprising the following steps:

[0038] The yeast β-glucan and mussel mucin are mixed according to the component ratio. If there are auxiliary materials and / or physiological seawater, the auxiliary materials and / or physiological seawater are added during the mixing process and mixed to obtain the product.

[0039] The third aspect of the present invention provides the use of the above composition, wherein the use is in preparing a product for improving nasal diseases.

[0040] According to some embodiments of the invention, the nasal cavity diseases include rhinitis, sinusitis and nasal polyps.

[0041] According to some embodiments of the present invention, the rhinitis includes acute rhinitis, chronic rhinitis and allergic rhinitis.

[0042] According to some embodiments of the present invention, the application is application in preparing a nasal cleaning product.

[0043] According to some embodiments of the present invention, the nasal cleaning product is used for nasal cleaning after rhinitis, nasal polyps, sinusitis or nasal tumor surgery and chemotherapy.

[0044] According to some embodiments of the present invention, the rhinitis includes acute rhinitis, chronic rhinitis and allergic rhinitis.

[0045] The fourth aspect of the present invention provides a product comprising the above composition, wherein the product is used to improve nasal diseases or clean the nasal cavity.

[0046] According to some embodiments of the present invention, the article comprises a drug and a medical device.

[0047] According to some embodiments of the present invention, the medicament further comprises a pharmaceutically acceptable excipient;

[0048] Furthermore, the auxiliary materials include at least one of a diluent, a filler, an adhesive, an absorption promoter, a surfactant, an adsorption carrier, a lubricant, and a flavoring agent.

[0049] The diluent may be commonly used in the art, including at least one of calcium sulfate, calcium bicarbonate, and calcium carbonate; the filler may be commonly used in the art, including at least one of starch, sucrose, and lactose; the binder may be commonly used in the art, including at least one of cellulose derivatives, alginate, gelatin, and polyvinyl pyrrolidone; the absorption enhancer may be a quaternary ammonium compound commonly used in the art; the surfactant may be cetyl alcohol commonly used in the art; the adsorption carrier may be commonly used in the art, including at least one of kaolin or bentonite; the lubricant may be commonly used in the art, including at least one of talc, calcium stearate, magnesium stearate, polyethylene glycol, glycerin, and caprylic / capric triglyceride; the flavoring agent may be commonly used in the art, including at least one of rose oil, rose essence, lemon oil, lemon essence, vanilla essence, vanillin, banana essence, pineapple essence, mint oil, orange peel oil, and apple essence.

[0050] According to some embodiments of the present invention, the dosage form of the drug is a gel, cream, solution, spray, patch, powder, ointment, drops, suppository, lozenge, granule, patch, capsule, tablet, or pill.

[0051] According to some embodiments of the invention, the medical device is a gel.

[0052] According to some embodiments of the present invention, the product is a nasal cleanser.

[0053] According to some embodiments of the present invention, the nasal cleanser further comprises a packaging container.

[0054] According to some embodiments of the present invention, the bottle body of the packaging container is made of polyethylene, polyester, polyvinyl chloride / low-density polyethylene oral liquid pharmaceutical composite hard sheet or aluminum.

[0055] According to some embodiments of the present invention, there are at least the following beneficial effects:

[0056] The present invention prepares a composition for improving rhinitis symptoms and nasal cleaning by rationally combining ultra-low molecular weight yeast β-glucan, low molecular weight yeast β-glucan, medium molecular weight yeast β-glucan, high molecular weight yeast β-glucan and mussel mucin. The composition can be effectively used for nasal cleaning of patients with nasal diseases such as acute rhinitis, chronic rhinitis, allergic rhinitis, nasal polyps, sinusitis, etc., and can also be used for nasal cleaning after nasal tumor surgery or chemotherapy. DETAILED DESCRIPTION

[0057] The following will clearly and completely describe the concept of the present invention and the technical effects produced in conjunction with the embodiments, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the embodiments described are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention. The test methods used in the embodiments are all conventional methods unless otherwise specified; the materials, reagents, etc. used, unless otherwise specified, can all be reagents and materials obtained from commercial channels.

[0058] The yeast beta-glucan used in the present invention has a beta-1,3-linked main chain and contains 1-2 beta-1,6-linked glucose side chains on every 3-7 main chain glucose residues on average.

[0059] Yeast β-glucans of varying molecular weights were prepared as follows: an appropriate amount of commercially available yeast β-glucan was dissolved in purified water and shaken to obtain a yeast β-glucan solution of approximately 40 mg / ml. The solution was then filtered through a 0.22 μm filter membrane. The swollen chromatographic filler was loaded onto a column and pressed using a purification method until the column achieved uniformity. After loading, the column was equilibrated with three column volumes of pure water. After equilibration, the sample was loaded at a concentration of 40 mg / ml. Elution was performed with pure water, and the first eluate was discarded. The eluates were then collected in separate steps and their molecular weight distribution was determined using high-performance gel permeation chromatography. The eluates with consistent polysaccharide molecular weight distribution were combined, concentrated, and freeze-dried. Ultra-low molecular weight yeast beta glucan with a molecular weight of less than 1WDa, low molecular weight yeast beta glucan with a molecular weight of 1WDa-50WDa, medium molecular weight yeast beta glucan with a molecular weight of 50WDa-200WDa, and high molecular weight yeast beta glucan with a molecular weight of more than 200WDa were prepared respectively.

[0060] Mussel mucin was purchased from Shenzhen Bergen Biotechnology Co., Ltd.

[0061] Physiological seawater is a 0.9% sodium chloride seawater solution.

[0062] Example 1

[0063] In this example, a composition for improving rhinitis symptoms and nasal cleaning was prepared, which was composed of the following components in weight percentage: 3% yeast β-glucan composition, 2% mussel mucin, 0.5% methylparaben, 0.1% sodium dihydrogen phosphate, and the balance being physiological seawater.

[0064] The yeast beta glucan composition comprises ultra-low molecular weight yeast beta glucan, low molecular weight yeast beta glucan, medium molecular weight yeast beta glucan and high molecular weight yeast beta glucan, and the mass ratio of ultra-low molecular weight yeast beta glucan, low molecular weight yeast beta glucan, medium molecular weight yeast beta glucan and high molecular weight yeast beta glucan is 1:2:1:2.

[0065] The preparation method is as follows: adding yeast beta glucan composition, mussel mucin and methylparaben into a portion of physiological seawater to dissolve, then adding sodium dihydrogen phosphate, and then adding the remaining amount of physiological seawater to obtain the product.

[0066] Example 2

[0067] This example prepared a composition for improving rhinitis symptoms and nasal cleaning, which is composed of the following components in weight percentage: 2% yeast beta glucan composition, 4% mussel mucin, 0.5% methylparaben, 0.1% sodium dihydrogen phosphate, and the balance being physiological seawater;

[0068] The yeast beta glucan composition comprises ultra-low molecular weight yeast beta glucan, low molecular weight yeast beta glucan, medium molecular weight yeast beta glucan and high molecular weight yeast beta glucan, and the mass ratio of ultra-low molecular weight yeast beta glucan, low molecular weight yeast beta glucan, medium molecular weight yeast beta glucan and high molecular weight yeast beta glucan is 1:2:1:2.

[0069] The specific preparation method is the same as that in Example 1.

[0070] Example 3

[0071] This example prepared a composition for improving rhinitis symptoms and nasal cleaning, which was composed of the following components in percentage by weight: 4% yeast beta glucan composition, 1% mussel mucin, 0.5% methylparaben, 0.1% sodium dihydrogen phosphate, and the balance being physiological seawater;

[0072] The yeast beta glucan composition comprises ultra-low molecular weight yeast beta glucan, low molecular weight yeast beta glucan, medium molecular weight yeast beta glucan and high molecular weight yeast beta glucan, and the mass ratio of ultra-low molecular weight yeast beta glucan, low molecular weight yeast beta glucan, medium molecular weight yeast beta glucan and high molecular weight yeast beta glucan is 1:3:2:1.

[0073] The specific preparation method is the same as that in Example 1.

[0074] Example 4

[0075] This example prepared a composition for improving rhinitis symptoms and nasal cleaning, which is composed of the following components in weight percentage: 3% yeast beta glucan composition, 2% mussel mucin, 0.5% methylparaben, 0.1% sodium dihydrogen phosphate, and the balance is physiological seawater;

[0076] The yeast beta glucan composition comprises low molecular weight yeast beta glucan, medium molecular weight yeast beta glucan and high molecular weight yeast beta glucan, and the mass ratio of the low molecular weight yeast beta glucan, the medium molecular weight yeast beta glucan and the high molecular weight yeast beta glucan is 2:1:2.

[0077] The specific preparation method is the same as that in Example 1.

[0078] Example 5

[0079] This example prepared a composition for improving rhinitis symptoms and nasal cleaning, which is composed of the following components in weight percentage: 3% yeast beta glucan composition, 2% mussel mucin, 0.5% methylparaben, 0.1% sodium dihydrogen phosphate, and the balance is physiological seawater;

[0080] The yeast beta glucan composition comprises ultra-low molecular weight yeast beta glucan, medium molecular weight yeast beta glucan and high molecular weight yeast beta glucan, and the mass ratio of the ultra-low molecular weight yeast beta glucan, the medium molecular weight yeast beta glucan and the high molecular weight yeast beta glucan is 1:1:2.

[0081] The specific preparation method is the same as that in Example 1.

[0082] Example 6

[0083] This example prepared a composition for improving rhinitis symptoms and nasal cleaning, which is composed of the following components in weight percentage: 3% yeast beta glucan composition, 2% mussel mucin, 0.5% methylparaben, 0.1% sodium dihydrogen phosphate, and the balance is physiological seawater;

[0084] The yeast beta glucan composition comprises ultra-low molecular weight yeast beta glucan, low molecular weight yeast beta glucan and high molecular weight yeast beta glucan, and the mass ratio of ultra-low molecular weight yeast beta glucan, low molecular weight yeast beta glucan and high molecular weight yeast beta glucan is 1:2:2.

[0085] The specific preparation method is the same as that in Example 1.

[0086] Example 7

[0087] This example prepared a composition for improving rhinitis symptoms and nasal cleaning, which is composed of the following components in weight percentage: 3% yeast beta glucan composition, 2% mussel mucin, 0.5% methylparaben, 0.1% sodium dihydrogen phosphate, and the balance is physiological seawater;

[0088] The yeast beta glucan composition comprises ultra-low molecular weight yeast beta glucan, low molecular weight yeast beta glucan and medium molecular weight yeast beta glucan, and the mass ratio of the ultra-low molecular weight yeast beta glucan, the low molecular weight yeast beta glucan and the medium molecular weight yeast beta glucan is 1:2:1.

[0089] The specific preparation method is the same as that in Example 1.

[0090] Comparative Example 1

[0091] This comparative example prepares a composition for improving rhinitis symptoms and nasal cleaning, which differs from Example 1 only in that the yeast β-glucan composition is omitted.

[0092] The specific preparation method is the same as that in Example 1.

[0093] Comparative Example 2

[0094] This comparative example prepares a composition for improving rhinitis symptoms and nasal cleaning, which differs from Example 1 only in that mussel mucin is omitted.

[0095] Test example

[0096] This test example tested the performance of the compositions for improving rhinitis symptoms and nasal cleaning prepared in Examples 1-7 and Comparative Examples 1-2.

[0097] 1. Observation Object

[0098] 100 volunteers aged 20-50 years old were recruited. They were patients with acute rhinitis, chronic rhinitis, and allergic rhinitis, and all of them gave informed consent.

[0099] 2. Usage

[0100] Grouping: The volunteers were divided into 10 groups, with 10 people in each group. The experimental groups were cleansed with the compositions for improving rhinitis symptoms and nasal cleaning prepared in Examples 1-7 and Comparative Examples 1-2, respectively, and the control group was cleansed with an equal amount of physiological seawater.

[0101] Usage: Volunteers in the experimental group used equal amounts of the compositions for improving rhinitis symptoms and nasal cleansing prepared in Examples 1-7 and Comparative Examples 1-2 to cleanse their nasal cavities, once in the morning and once in the evening. The control group differed from the experimental group in that the nasal cavities were cleansed with equal amounts of physiological seawater. Observation lasted 15 days.

[0102] (3) Efficacy assessment:

[0103] 1) Marked effect: Rhinitis symptoms completely disappear;

[0104] 2) Effective: rhinitis symptoms were relieved;

[0105] 3) Ineffective: No change in symptoms.

[0106] Table 1

[0107]

[0108] The results are shown in Table 1. It can be seen from the table that the composition for improving rhinitis symptoms and nasal cleaning prepared in the embodiment of the present invention can effectively improve rhinitis symptoms.

[0109] While the embodiments of the present invention have been described in detail above, the present invention is not limited to the embodiments described above. Various modifications may be made within the scope of knowledge possessed by a person skilled in the art without departing from the spirit of the present invention. Furthermore, the embodiments of the present invention and the features thereof may be combined with one another unless there is a conflict.

Claims

1. A composition for improving rhinitis symptoms, characterized in that: The active ingredients are 0.1 to 7 parts of yeast beta-glucan and 0.1 to 6 parts of mussel mucin in parts by weight; The yeast β-glucan is composed of ultra-low molecular weight yeast β-glucan, low molecular weight yeast β-glucan, medium molecular weight yeast β-glucan and high molecular weight yeast β-glucan; The molecular weight of the ultra-low molecular weight yeast β-glucan is less than 1WDa; The molecular weight of the low molecular weight yeast β-glucan is 1WDa to 50WDa; The molecular weight of the medium molecular weight yeast β-glucan is 50WDa to 200WDa; The molecular weight of the high molecular weight yeast β-glucan is >200 WDa; The mass ratio of the ultra-low molecular weight yeast β-glucan, the low molecular weight yeast β-glucan, the medium molecular weight yeast β-glucan and the high molecular weight yeast β-glucan is 1:(1-4):(1-2):(1-3); The total mass percentage of the yeast β-glucan and mussel mucin in the composition is 1% to 7%; The improvement of rhinitis symptoms refers to the improvement of acute rhinitis, chronic rhinitis, and allergic rhinitis symptoms.

2. The composition according to claim 1, characterized in that The composition also includes physiological seawater and / or sodium dihydrogen phosphate.

3. The composition according to claim 1, characterized in that The composition further comprises 0.1 to 20 parts of auxiliary materials.

4. The composition according to claim 3, characterized in that The auxiliary materials include at least one of preservatives, thickeners, wetting agents and moisturizers.

5. The composition according to claim 4, characterized in that The preservative includes at least one of methylparaben, benzoic acid, sodium benzoate, phenoxyethanol, sorbic acid or sodium sorbate.

6. The composition according to claim 1, characterized in that The composition is composed of the following components in parts by weight: Yeast β-glucan 0.1-7 parts; 0.1-6 parts of mussel mucin; 0.1-1 parts of preservatives; 0.05-0.5 parts of sodium dihydrogen phosphate; Appropriate amount of physiological seawater.

7. A method for preparing the composition according to any one of claims 1 to 6, characterized in that: The method comprises the following steps: mixing the yeast beta-glucan and mussel mucin according to the component ratio, adding the auxiliary materials and / or physiological seawater, if any, during the mixing process, and mixing to obtain the product.

8. Use of the composition according to any one of claims 1 to 6 in the preparation of a product for improving rhinitis symptoms; wherein the improving rhinitis symptoms is improving the symptoms of acute rhinitis, chronic rhinitis, or allergic rhinitis.

9. A product for improving rhinitis symptoms, characterized in that: The product comprises the composition according to any one of claims 1 to 6; the product is a medicine or a medical device; and the improvement of rhinitis symptoms is improvement of acute rhinitis, chronic rhinitis, and allergic rhinitis symptoms.

Images